Form 4: Revolution Medicines CFO Sells Shares to Cover Tax Obligations Under Pre-Arranged Plan

Revolution Medicines, Inc. Chief Financial Officer, Jack Anders, sold 2,170 shares of common stock on June 16, 2025, at a weighted average price of $39.83 per share, primarily to satisfy tax withholding obligations related to restricted stock unit vesting.

Summary

• Jack Anders, Chief Financial Officer of Revolution Medicines, Inc. (RVMD), reported the sale of 2,170 shares of the company's common stock.
• The transaction occurred on June 16, 2025, with a weighted average sale price of $39.83 per share, ranging from $39.5913 to $39.8291.
• This sale was executed pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023, specifically to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs) after July 15, 2023.
• Following this transaction, Mr. Anders beneficially owns 113,314 shares of common stock, which includes 478 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025, and 54,213 RSUs.

Sentiment

Score: 6

Explanation: The transaction is a routine insider sale for tax purposes under a pre-arranged plan, which is generally neutral to slightly positive as it indicates a planned, non-discretionary sale. It does not reflect a negative outlook on the company by the insider.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 plan, indicating it was a scheduled transaction and not a discretionary sale based on new negative information.
• The stated purpose of the sale was to cover tax withholding obligations, which is a common and expected reason for executive stock sales related to equity compensation.

Negatives

• The transaction results in a reduction of direct share ownership by a key executive, which, while for tax purposes, is still a decrease in insider holdings.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance, strategic direction, or financial outlook. It solely reports an insider transaction.

Management Comments

• "Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ('RSUs') after July 15, 2023."
• "This transaction was executed in multiple trades in prices ranging from $39.5913 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price."
• "The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction, specifically for tax purposes, and does not provide information relevant to broader industry trends or competitive dynamics within the biotechnology or pharmaceutical sector. Such transactions are common for executives receiving equity compensation across all industries.

Comparison to Industry Standards

• This document reports a standard insider transaction for tax purposes, which is a common practice across all industries for executives with equity compensation.
• There are no specific comparable companies, projects, or results mentioned that would allow for a detailed industry comparison beyond the general observation that such sales are routine for tax obligations.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in direct ownership by a key executive, but its pre-planned nature for tax purposes mitigates concerns about insider sentiment, suggesting no negative implications for company prospects.
• Employees: The transaction is related to executive compensation (RSUs), which is a standard component of employee incentive programs and does not indicate any direct impact on the broader employee base.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each respective price within the reported range upon request by the SEC staff, the Issuer, or a security holder.

Key Dates

Recommendation

Keywords

Revolution Medicines, RVMD, Form 4, Insider Trading, Stock Sale, Executive Compensation, Jack Anders, CFO, Rule 10b5-1, Restricted Stock Units, Tax Withholding